APA

Ip M. S., Oden N. L., Scott I. U., VanVeldhuisen P. C., Blodi B. A., Ghuman T. & Baker C. W. (20191125). Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study. : JAMA ophthalmology.

Chicago

Ip Michael S, Oden Neal L, Scott Ingrid U, VanVeldhuisen Paul C, Blodi Barbara A, Ghuman Thomas and Baker Carl W. 20191125. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study. : JAMA ophthalmology.

Harvard

Ip M. S., Oden N. L., Scott I. U., VanVeldhuisen P. C., Blodi B. A., Ghuman T. and Baker C. W. (20191125). Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study. : JAMA ophthalmology.

MLA

Ip Michael S, Oden Neal L, Scott Ingrid U, VanVeldhuisen Paul C, Blodi Barbara A, Ghuman Thomas and Baker Carl W. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes With Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study. : JAMA ophthalmology. 20191125.